| Cat.No. | Name | Information |
|---|---|---|
| M6189 | Ossirene | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta (IL-1β) converting enzyme. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene also inhibits Caspase-1. |
| M6223 | Tocilizumab | Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. Tocilizumab prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the research of rheumatoid arthritis and COVID-19. |
| M10139 | Anakinra | Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. |
| M24655 | Sonelokimab | Sonelokimab (ALX 0761; M 1095) is a trivalent nanobody comprised of monovalent camelid-derived nanobodies specific to human interleukin (IL)-17A, IL-17F, and human serum albumin VHHs. Sonelokimab has the potential for plaque-type psoriasis research. |
| M24620 | Guselkumab | Guselkumab is a recombinant human IgG1 monoclonal antibody against the IL-23p19 subunit. Guselkumab binds to human and cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab inhibits production of cytokines lying downstream of the IL-23 signaling pathway and can be used for psoriatic arthritis research. |
| M24614 | Tildrakizumab | Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis. |
| M24573 | Dupilumab | Dupilumab (dupilumab) is a potentially first-in-class, fully human monoclonal antibody against IL-4 receptor alpha (IL-4Rα) that inhibits IL-4 and IL-13 signaling and can be used in studies related to atopic dermatitis and asthma. |
| M24566 | Brodalumab | Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis. |
| M24556 | Ixekizumab | Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL-17A binding to IL-17RA (IL-17A receptor) but does not bind to other IL-17 family members. Ixekizumab is used for the research of moderate-to-severe plaque psoriasis. |
| M24542 | Tralokinumab | Tralokinumab, a fully human IgG4 monoclonal antibody, specifically binds with high affinity to IL-13 alone, preventing its interaction with the receptor and subsequent downstream signalling. Tralokinumab can be used for the research of the atopic dermatitis (AD). |
| M22522 | IL-17A inhibitor 1 | IL-17A inhibitor 1 is a IL-17A inhibitor, with IC50 values of <9.45 nM and 9.3 nM in alphalisa assay and HT-29 cells. |
| M21628 | 2'-Fucosyllactose | 2'-Fucosyllactose (2'-FL) is an oligosaccharide that could be derived from human milk. 2'-Fucosyllactose regulates the expression of CD14, alleviates colitis and regulates the gut microbiome. 2'-Fucosyllactose stimulates T cells to increase IFN-γ production and decreases IL-6, IL-17, and TNF-α production of cytokines. |
| M21444 | GP130 receptor agonist-1 | GP130 receptor agonist-1 is a potent, brain-penetrant and orally active GP130 receptor agonist. GP130 receptor agonist-1 has a neuroprotective effect on NMDA-induced neurotoxicity. |
| M20846 | Hydrocortisone sodium succinate | Hydrocortisone sodium succinate (Hydrocortisone 21-hemisuccinate sodium salt) has significant inhibitory effects on the IL-6 bioactivity with IC50 of 6.7 μM. Hydrocortisone sodium succinate can bind to glucocorticoid receptor, initiating the transcription of anti-inflammatory and immunosuppressive mediators. |
| M20724 | RCM-1 | RCM-1 is a nontoxic inhibitor of Forkhead box M1 (FOXM1) that suppresses goblet cell metaplasia and prevents IL-13 and STAT6 signaling in allergen-exposed mice. RCM-1 decreases carcinogenesis and nuclear β-catenin. |
| M20539 | Montelukast | Montelukast is a potent, selective and orally active cysteinyl leukotriene receptor 1 (CysLT1) antagonist with antioxidant activity for studies related to asthma and liver injury. |
| M11349 | Deoxyandrographolide | Deoxyandrographolide inhibited lPS-induced iNOS mRNA and the production of pro-inflammatory mediators TNF-α and IL-6. Deoxyandrographolide enhances neurite growth induced by NGF. |
| M11172 | Reslizumab | Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin 5 (IL-5) for the study of eosinophilic asthma. Reslizumab effectively blocks il-5 function. Reslizumab inhibited IL-5-dependent cell proliferation with an IC50 of about 91.1 pM. |
| M11086 | RCGD423 | RCGD423 is a gp130 regulator that prevents joint cartilage degeneration and promotes its repair. |
| M10686 | Muscone | Muscone is the main active monomer of Chinese medicinal musk. Muscone inhibits activation of NF-κB and NLRP3 inflammatory bodies. Muscone significantly lowers inflammatory cytokine (IL-1β, TNF-α, and IL-6) levels and ultimately improves heart function and survival. |
| M10559 | Tyrphostin A1 | Tyrphostin A1 is a weaker EGFR tyrosine kinase inhibitor, Tyrphostin A1 inhibits CD40L-stimulated IL-12 production in macrophage cultures and antigen-induced generation of Th1 cells. |
| M10159 | Kaempferol 3-O-β-D-glucuronide | Kaempferol 3-O-β-D-glucuronide is a conjugated kaempferol metabolite, which has anti-inflammatory effect. |
| M9868 | GIBH-130 | GIBH-130 is a neuroinflammation inhibitor, with IC50 value of 3.4 nM for suppressing the IL-1β secretion by activated microglia. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
